| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 03/02/1999 | US5877224 Polymeric drug formulations |
| 03/02/1999 | US5877210 Controlling immune response |
| 03/02/1999 | US5877205 Parenteral paclitaxel in a stable non-toxic formulation |
| 03/02/1999 | US5877169 Methods of treatment of ischemic damage |
| 03/02/1999 | US5877160 Compositions and methods of treatment of androgen-associated baldness using antisense oligomers |
| 03/02/1999 | US5877158 Pro-prodrugs, their production and use |
| 03/02/1999 | US5877149 Calibration topical cream or gel |
| 03/02/1999 | US5876989 Transfer of molecules into the cytosol of cells |
| 03/02/1999 | US5876969 Fusion polypeptide of therapeutic polypeptides attatched to c-and n-terminals of human serum albumin; for high plasma stability, minimization of dosage, side effect reduction |
| 03/02/1999 | US5876950 Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy |
| 03/02/1999 | US5876752 Use of interfacially-polymerized membranes in delivery devices |
| 03/02/1999 | US5876750 Dosage form comprises a laminated wall for maintaining the integrity of the dosage form and of the antiepileptic drug. |
| 03/02/1999 | US5876746 Transdermal patch and method for administering 17-deacetyl norgestimate alone or in combination with an estrogen |
| 03/02/1999 | US5876744 Highly bioadhesive and mucoadhesive compositions containing polyvinyl alcohol, polycarbophil and biopolymer for the treatment of skin conditions and as vehicles for active ingredients |
| 03/02/1999 | US5876727 Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same |
| 03/02/1999 | US5876695 Nuclear magnetic resonance contrast agent |
| 03/02/1999 | US5876692 Non-lethal methods for conditioning a recipient for bone marrow transplantation |
| 03/02/1999 | US5876691 Screening a bacteriophage library; diagnosis of colorectal tumors |
| 03/02/1999 | CA2062001C Stabilized pvp-i solutions |
| 02/28/1999 | CA2246224A1 Chroman derivative containing ophthalmic solution |
| 02/25/1999 | WO1999009412A1 Functional fragments of hiv-1 vpr protein and methods of using the same |
| 02/25/1999 | WO1999009142A1 Encapsulation of living tissue cells in a microsphere |
| 02/25/1999 | WO1999009057A2 Hybrid tetanus toxoid proteins that migrate retrogradely and transynaptically into the cns |
| 02/25/1999 | WO1999009052A1 Chemical modification of proteins to improve biocompatibility and bioactivity |
| 02/25/1999 | WO1999009051A1 Method for the induction of proteins with therapeutic effect |
| 02/25/1999 | WO1999009037A1 Phospholipid analogue compounds |
| 02/25/1999 | WO1999008997A1 Novel lipopolyamines, and the preparation and use thereof |
| 02/25/1999 | WO1999008718A2 Bioresorbable compositions for implantable prostheses |
| 02/25/1999 | WO1999008711A1 Lipid-polyamide conjugates and compositions for nucleic acid delivery |
| 02/25/1999 | WO1999008710A1 BIOTHERAPY OF CANCER BY TARGETING TP-3/p80 |
| 02/25/1999 | WO1999008704A1 Method of protecting against chronic infections |
| 02/25/1999 | WO1999008690A1 Method of enhancing bioavailability of fexofenadine and its derivatives |
| 02/25/1999 | WO1999008684A2 Solutions containing azasteroids |
| 02/25/1999 | WO1999008676A1 Compositions containing bergamottin for increasing the oral bioavailability of pharmaceutical agents |
| 02/25/1999 | WO1999008666A2 Pharmaceutical composition comprising an azateroid |
| 02/25/1999 | WO1999008663A1 Parenteral pimaricin as treatment of systemic infections |
| 02/25/1999 | WO1999008660A1 Solid pharmaceutical dosage forms in form of a particulate dispersion |
| 02/25/1999 | WO1999008658A1 Fast-dissolving comestible units formed under high-speed/high-pressure conditions |
| 02/25/1999 | WO1999008657A2 Self-binding shearform compositions |
| 02/25/1999 | WO1999008651A1 Skin care compositions and use |
| 02/25/1999 | WO1998052613A3 Method of administration for a therapeutic agent utilizing suitable forms of hyaluronic acid and combinations with electroporation |
| 02/25/1999 | WO1998033808A3 A reversible stoichiometric process for conjugating biomolecules |
| 02/25/1999 | DE19735776A1 New neutral or cationic phospholipid analogues |
| 02/25/1999 | CA2301295A1 Functional fragments of hiv-1 vpr protein and methods of using the same |
| 02/25/1999 | CA2301228A1 Fast-dissolving comestible units formed under high-speed/high-pressure conditions |
| 02/25/1999 | CA2295478A1 Parenteral pimaricin as treatment of systemic infections |
| 02/25/1999 | CA2295023A1 Solutions containing azasteroids |
| 02/25/1999 | CA2295016A1 Pharmaceutical composition |
| 02/24/1999 | EP0898170A2 Detergent-containing gold conjugates |
| 02/24/1999 | EP0897983A2 Antibody against CD40-L |
| 02/24/1999 | EP0897392A1 Isolation and use of sh3 binding peptides |
| 02/24/1999 | EP0897300A1 Treatment of pruritus with vitamin d and analogs thereof |
| 02/24/1999 | EP0897264A1 Natural antioxidant composition |
| 02/24/1999 | EP0597101B1 STABILIZED HUMAN MONOCLONAL CLN-IgG ANTIBODY PREPARATION |
| 02/24/1999 | CN1209069A Covalent lipit-phosphono-carboxylic acid conjugates and application thereof as antiviral medicaments |
| 02/24/1999 | CN1209068A Hyaluronic acid as DNA carrier for gene therapy and VEGF antisense DNA to treat abnormal retinal vascularization |
| 02/24/1999 | CN1209067A Stabilisers for live vaccines |
| 02/24/1999 | CN1209059A Taxane compositions and method for producing same |
| 02/24/1999 | CN1209056A Stable topical compositions |
| 02/24/1999 | CN1208616A Sustained release and implantation type cis-platinum medicine and method for preparing same |
| 02/24/1999 | CN1042198C Multile emulsions |
| 02/23/1999 | US5874573 Cyclic amine derivatives |
| 02/23/1999 | US5874552 For solid state oligonucleotide synthesis |
| 02/23/1999 | US5874540 CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies |
| 02/23/1999 | US5874500 Crosslinked polymer compositions and methods for their use |
| 02/23/1999 | US5874450 Aqueous buffered solution having alkaline ph containing a sleep promoting amount of doxylamine and anionic surfactants selected from long chain hydrocarbon sulfonates or carboxylates |
| 02/23/1999 | US5874418 Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use |
| 02/23/1999 | US5874408 Stabilized albumin-free recombinant factor VII preparation having a low sugar content |
| 02/23/1999 | US5874406 Synthetic peptide analogs of lung surface protein SP-C |
| 02/23/1999 | US5874402 Use of cell membrane permeants in the treatment of cellular proliferative diseases |
| 02/23/1999 | US5874297 Treatment of genetic disorders |
| 02/23/1999 | US5874225 Cell line from human rhabdomyosarcoma cell line te671. differentiated cells are characterized by great enlargement |
| 02/23/1999 | US5874111 Process for the preparation of highly monodispersed polymeric hydrophilic nanoparticles |
| 02/23/1999 | US5874107 Sustained release tablet containing diclofenac-Na and methylhydroxypropyl-cellulose as a sustained release agent |
| 02/23/1999 | US5874099 Methods for making immunoisolatary implantable vehicles with a biocompatible jacket and a biocompatible matrix core |
| 02/23/1999 | US5874095 Pharmaceutical active material, non-ionic crosslinked polyacrylamide having a molecular weight of from 1,000,000 to 30,000,000, the polyacrylamide being predispersed in a water-immiscible oil containing a surfactant |
| 02/23/1999 | US5874086 Synthetic polypeptide analogs of parathyroid hormone (pth), parathyroid hormone related peptide (pthrp), and of the physiologically active truncated homologs and analogs of pth and pthrp; forming an amphipathic alpha-helix |
| 02/23/1999 | US5874081 Therapeutic compositions and methods for inhibition and treatment of tumor associated angiogenesis |
| 02/23/1999 | US5874075 Stable protein: phospholipid compositions and methods |
| 02/23/1999 | US5874064 Aerodynamically light particles for pulmonary drug delivery |
| 02/23/1999 | CA1340409C Functionally specific antibodies |
| 02/20/1999 | CA2213385A1 Method of protecting against coccidiosis infections in poultry |
| 02/18/1999 | WO1999007749A1 Complex chemical compound, synthesis and various applications of said compound |
| 02/18/1999 | WO1999007744A1 Polysaccharide conjugates of biomolecules |
| 02/18/1999 | WO1999007728A2 Linear peptides derived from antibiotic peptides, preparation and use for vectoring active substances |
| 02/18/1999 | WO1999007723A1 Nucleic acid uptake and release vehicle |
| 02/18/1999 | WO1999007418A2 Sterile bioerodible implant device with improved biocompatability and method |
| 02/18/1999 | WO1999007417A1 Hemostatic tissue sealants |
| 02/18/1999 | WO1999007416A1 TEMPERATURE-CONTROLLED pH-DEPENDANT FORMATION OF IONIC POLYSACCHARIDE GELS |
| 02/18/1999 | WO1999007414A1 Vectors derived from antibodies for transferring substances into cells |
| 02/18/1999 | WO1999007396A1 Composition comprising propolis and at least an essential oil |
| 02/18/1999 | WO1999007383A1 Composition and method for regulating cell proliferation and cell death |
| 02/18/1999 | WO1999007370A1 Oral solid pharmaceutical compositions containing nicorandil for a modulated release and the process for their preparation |
| 02/18/1999 | WO1999007362A1 A PROCESS FOR STABIlIZING LEVOGYRE ASCORBIC ACID (LAA) AND STABLE LAA COMPOSITIONS |
| 02/18/1999 | WO1999007347A1 Aqueous viscous compositions, whether clear or not, for making soft or hard capsules, and method for making films for such capsules |
| 02/18/1999 | WO1999007343A1 Injectable biodegradable block copolymer gels for use in drug delivery |
| 02/18/1999 | WO1999007342A1 Prolonged release active agent dosage form adapted for gastric retention |
| 02/18/1999 | WO1999007341A1 Compositions for nasal administration |
| 02/18/1999 | WO1999007324A2 Conjugates targeted to the interleukin-2 receptor |
| 02/18/1999 | WO1999007237A1 Composition comprising a liquid absorbed on a support based on precipitate silica |